Samuel D. Isaly
Portfolio Manager at Eaton Vance Worldwide
Member since: Aug '04 · 4 Opinions
Rating Card
| All | 
Rating
| 
Big Win
| 
Win
| 
Neutral
| 
Loss
| 
Big Loss
|  |
|---|---|---|---|---|---|---|---|
| 0 | 0 0.00% | 0 0.00% | 0 0.00% | 0 0.00% | 0 0.00% |
Stock Opinions by Samuel D. Isaly
TOP PICK
Growing very well. Their biggest drug is for high blood pressure but also have a good product line for cancer treatment. Not many patent exposures in the near-term.
biotechnology / pharmaceutical
$45.760
Owned
TOP PICK
Lots of new products. Rapid profit growth.
biotechnology / pharmaceutical
TOP PICK
A very rapidly growing company. Earnings per share growth is in excess of 20% yearly. PE ratio barely more than that.
biotechnology / pharmaceutical
TOP PICK
Has a low market cap. Have a drug that extends life in lung cancer which should be approved around the turn of the year.
biotechnology / pharmaceutical
Showing 1 to 4
of 4 entries
- «
- ‹
- 1
- ›
- »
